SCHEMBL4571012

SCHEMBL4571012

COc1cc2c(cc1OC)Sc1cc(OC)c(OC)cc1Sc1cc(OC)c(OC)cc1S2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.46
MAPT P10636 2/20 0.46
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 3/20 0.42
CA2 P00918 3/20 0.42
ACHE P22303 3/20 0.42
CA9 Q16790 3/20 0.42
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA7 P43166 2/20 0.42
CA14 Q9ULX7 2/20 0.42
HPGD P15428 1/20 0.39
KLK7 P49862 1/20 0.39
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2A Q12879 1/20 0.39
GRIN2B Q13224 1/20 0.39
GRIN2C Q14957 1/20 0.39
GRIN3A Q8TCU5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29422790 1.00 CYP3A4 (0.46) CYP3A4MAPTALDH1A1KDM4ECA2
SCHEMBL1201869 1.00 CYP3A4 (0.46) CYP3A4MAPTALDH1A1KDM4ECA2
SCHEMBL9511322 0.82 GAA (0.50) MAPTALDH1A1KDM4EHPGDTSHR
SCHEMBL9507682 0.82 GRIN2D (0.44) ALDH1A1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL3051919 0.80 CYP3A4 (0.36) CYP3A4MAPTALDH1A1KDM4ECA2
SCHEMBL28383858 0.80 SNCA (0.53) CYP3A4MAPTALDH1A1KDM4EACHE
SCHEMBL38661182 0.80 CYP3A4 (0.36) CYP3A4MAPTALDH1A1KDM4ECA2
SCHEMBL1276533 0.75 CYP3A4 (0.59) CYP3A4MAPTALDH1A1KDM4ECA2
SCHEMBL4561971 0.73 CYP3A4 (0.39) CYP3A4MAPTALDH1A1KDM4ECA2
SCHEMBL13518528 0.69 CYP3A4 (0.53) CYP3A4MAPTALDH1A1KDM4ECA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173803-B2 Supramolecular scaffolds and methods of making the same LOYOLA UNIVERSITY OF CHICAGO (US) 2012-05-08 US disclosed
US-8173803-B2 Supramolecular scaffolds and methods of making the same LOYOLA UNIVERSITY OF CHICAGO (US) 2012-05-08 US disclosed
US-20100041880-A1 Supramolecular Scaffolds and Methods of Making the Same LOYOLA UNIVERSITY OF CHICAGO (US) 2010-02-18 US disclosed
US-20100041880-A1 Supramolecular Scaffolds and Methods of Making the Same LOYOLA UNIVERSITY OF CHICAGO (US) 2010-02-18 US disclosed
EP-0576492-A1 MACROCYCLIC THIOETHER LIGANDS AND THEIR USE AS INTERMEDIATES FOR BINDING IONS TO SUBSTRATES BRITISH TECHNOLOGY GROUP LTD (GB) 1994-01-05 EP disclosed
WO-1992016520-A1 MACROCYCLIC THIOETHER LIGANDS AND THEIR USE AS INTERMEDIATES FOR BINDING IONS TO SUBSTRATES BRITISH TECHNOLOGY GROUP LTD (GB) 1992-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041880-A1 Supramolecular Scaffolds and Methods of Making the Same BLM, TBXAS1, TOP2B CYP3A4 175/4885MAPT 2040/4885ALDH1A1 1363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.